Skip to main content

ProBio is now licensing the CHOK1 cell line development system to biopharma companies for commercial use

By: Get News

CHOK1-GenS&CHOK1-ADCC+

Cell Line Development System Commercial License

ProBio has 12 years of experience in mammalian cell line development, and is one of the earliest companies getting the CHO-K1 - CHO commercial license for commercial use and sublicense agreement from ECACC.

ProBio has two cell line development systems: wild-type cell line CHOK1-GenS and ADCC-enhanced cell line CHOK1-ADCC +. CHOK1-GenS cell line development system without chemical . Developed ADCC enhanced host cell line (CHOK1-ADCC+), which can produce afucosylated monoclonal antibodies with enhanced ADCC activity. They are in together with the high-expression proprietary pGenHT 1.0-UP vector, the average titer of mAb is 5.7 g/L, the maximum titer of mAb is up to 15 g/L.

CHOK1 system exclusive advantages

IP Clear

• ECACC license agreement• Proprietary pGenHT 1.0-UP vector

Royalty Free

• One-time payment without royalty

2 CHO-K1 Host Cell License to Choose

• Wide type CHOK1-GenS• ADCC enhanced CHOK1-ADCC+

Combo license at discounted price

• Purchase in combination with wild type CHOK1-GenS cell line, and get a discounted price

Suitable for different type of proteins

• mAb/Protein

• BsAb,etc

Fulfill the regulatory requirements

• Fulfill the regulatory requirements of FDA,EMA and NMPA

Case Study of CHOK1-GenS cell line system

High productivity with CHOK1-GenS system

  • Suitable for different type of molecules

 Excellent stability with CHOK1-GenS system

  • The titer at the end of stability study during fed-batch is recorded as T2.
  • The titer at the beginning of stability study during fed-batch is recorded as T1.
  • Titer variation=(T2-T1)/T1*100%
  • Titer variation should be within 30%.

 

High productivity with CHOK1-GenS system

Titer prior to cell culture up to 15 g/L

Excellent Stability in Scale-Up from 3L to 200L

Case Study of CHOK1-ADCC+ cell line system

CD16a 158V/F affinity (BLI)

The affinity to CD16a (158V and 158F) was increased by 3-4 times.

PBMC-based ADCC

  • Cytotoxicity is increased by about 10%.
  • Effect concentration (EC50) was reduced by 6 times.
  • ADCC effect was significantly enhanced.

CHOK1 delivery package

Media Contact
Company Name: ProBio CDMO
Email: Send Email
Phone: 1-877-436-7274 (Toll-Free)
Country: United States
Website: https://www.probiocdmo.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  210.64
+2.08 (1.00%)
AAPL  274.23
+2.09 (0.77%)
AMD  213.84
+0.00 (0.00%)
BAC  51.69
+1.28 (2.54%)
GOOG  313.03
+2.11 (0.68%)
META  653.69
+14.39 (2.25%)
MSFT  389.00
+0.00 (0.00%)
NVDA  195.56
+2.71 (1.41%)
ORCL  147.89
+1.75 (1.20%)
TSLA  417.40
+8.02 (1.96%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.